| I-022 Jeff Barrett Open-science solutions enabled within a digital research environment to support MIDD (Model Informed Drug Development) and precision dosing Wednesday 10:20-11:50 |
| I-041 Divya Brundavanam Addressing Confounding Bias in Exposure-Response Analysis: Evaluating Instrumental Variable Modeling Strategies Wednesday 10:20-11:50 |
| I-064 Limei Cheng Using machine learning to predict longitudinal platelet counts: a methodology framework Wednesday 10:20-11:50 |
| I-082 Wilbert de Witte In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models Wednesday 10:20-11:50 |
| I-085 Abdallah Derbalah Beyond the Liver; In Silico Screening for Tissue-Specific Oligonucleotide Delivery Receptors Wednesday 10:20-11:50 |
| I-097 Jeroen Elassaiss-Schaap Construction of IMPRES-M, a non-parametric impulse-response modeling method, in the context of varying pharmacokinetic profiles Wednesday 10:20-11:50 |
| I-102 Ali Farnoud A Neural Networks-assisted NLME Framework: Case Study on Modeling Platelet Counts Wednesday 10:20-11:50 |
| I-106 Lucie FAYETTE Using Fisher Information Matrix to predict covariate effects in forest plots and power of their relevance Wednesday 10:20-11:50 |
| I-109 Matthew Fidler nlmixr2, rxode2 and Monolix: interchangeable models using monolix2rx and babelmixr2 Wednesday 10:20-11:50 |
| I-111 Nuria Folguera-Blasco Coupling Quantitative Systems Pharmacology (QSP) and ML/AI: a story of pAIns and gAIns Wednesday 10:20-11:50 |
| II-006 Stefano Giampiccolo Supporting pharmacometrics applications by robust parameter estimation and identifiability analysis using hybrid Neural ODEs Wednesday 15:20-16:50 |
| II-007 Asina Gijasi Structural model development with compartmental pharmacokinetic models for a range of small molecule subcutaneous data Wednesday 15:20-16:50 |
| II-013 Sebastiaan Goulooze The drug titration paradox in the presence of intra-individual variation: can we estimate the true concentration-effect relationship? Wednesday 15:20-16:50 |
| II-023 Sofia Guzzetti A modelling framework for in vitro/in vivo translation of PROTACs PK/PD and PK/Efficacy: accelerating drug discovery of targeted protein degraders Wednesday 15:20-16:50 |
| II-029 Niklas Hartung A unified Rodgers et al. model for predicting tissue partitioning reveals the need for a theoretical derivation of the Lukacova et al. (Simulations Plus) model Wednesday 15:20-16:50 |
| II-044 Nathanaël Hozé A multi-scale modelling framework to assess the relationship between SARS-CoV-2 viral load and transmission in household studies. Wednesday 15:20-16:50 |
| II-046 Zhe Huang Model-integrated bioequivalence method for highly variable drugs with long half-life: a simulation study comparing complete washout and incomplete washout designs Wednesday 15:20-16:50 |
| II-048 Zhonghui Huang Development and evaluation of nlmixr2auto: Automated open-source model building Wednesday 15:20-16:50 |
| II-056 Ludvig Jakobsson A frailty model for quantifying the association between CompEx risk and variation in lung function in asthma Wednesday 15:20-16:50 |
| II-058 Alexander Janssen Time-dependent random effects. Wednesday 15:20-16:50 |
| II-059 Hyeseon Jeon Comparative Study of Target Mediated Drug Disposition Approximation Methods Based on Validity Conditions: Application to Clinical Trial Studies Wednesday 15:20-16:50 |
| II-066 Christos Kaikousidis Quantification of model misspecification of population pharmacokinetic models by a machine learning postprocessing correction of the residual variability Wednesday 15:20-16:50 |
| II-092 Alexandra Lavalley-Morelle Extending the R open-source saemix package: a new tool for parametric joint models Wednesday 15:20-16:50 |
| II-093 Jacob Leander Simulation-based comparison of MMRM and dose-response MMRM for Ph2b dose-finding design in rheumatoid arthritis Wednesday 15:20-16:50 |
| II-098 Cristina Leon Enhancing statistical power in lipid-lowering therapy studies through optimization of the MACE endpoint composition: a model-based meta-analysis approach Wednesday 15:20-16:50 |
| II-105 Andreas Lindauer A Mini-Tutorial on Campsis: The R-Based PK/PD Simulation Suite Wednesday 15:20-16:50 |
| II-114 Cifelli Lorenzo ODE-free survival modeling with full pharmacokinetic profiles in the IMPRES-M framework Wednesday 15:20-16:50 |
| II-115 Mark Lovern Introducing InSilicoTrials NONMEM simulator: Cloud-based simulation tool for NONMEM models Wednesday 15:20-16:50 |
| III-002 Moustafa M. A. Ibrahim The reference corrected VPC – A more intuitive model diagnostic Thursday 09:50-11:20 |
| III-003 Panos Macheras Understanding the gastrointestinal absorption of drugs using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models: Focus on Biowaivers Thursday 09:50-11:20 |
| III-004 Paolo Magni Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients Thursday 09:50-11:20 |
| III-008 Jialin Mao Human PK prediction of Kras G12C covalent inhibitors: GDC-6036, AMG-510 and MRTX-849 using PBPK approach Thursday 09:50-11:20 |
| III-017 Enrico Mastrostefano Integrating PKPD and Agent-Based Modeling to Explore Tuberculosis Relapse after Treatment. Thursday 09:50-11:20 |
| III-081 Elba Raimundez Alvarez Evaluation of automated model development workflows for population pharmacokinetic models Thursday 09:50-11:20 |
| III-086 Freek Relouw Towards an Inflammation Simulation Model: Development and Validation of a Mathematical Model of the Human Inflammatory Response to Acute and Prolonged Lipopolysaccharide Exposure Thursday 09:50-11:20 |
| III-104 Mark Sale Performance of Machine Learning Algorithms for Model Selection Thursday 09:50-11:20 |
| III-106 Sergio Sánchez Herrero Individualized Prediction of Gentamicin Concentration in Neonates: A Multimodal Approach of PBPK Modeling and Machine Learning Thursday 09:50-11:20 |
| III-112 Franziska Schädeli Stark Performance evaluation of the Automatic Model Development (AMD) tool with real population pharmacokinetic datasets from clinical drug development projects Thursday 09:50-11:20 |
| IV-019 Marie Steinacker Combining biological knowledge and machine learning for predicting dynamics of haematotoxcity after chemotherapy: a comparative analysis Thursday 15:00-16:30 |
| IV-030 Sebastian Tandar Population-level treatment optimization using a multi-objective optimization strategy Thursday 15:00-16:30 |
| IV-035 Donato Teutonico Estimation of population parameter values and variability coupling non-linear mixed-effects modeling (based on SAEM algorithm) with a whole-body PBPK model Thursday 15:00-16:30 |
| IV-043 Mirjam Trame FOCE generalized log-likelihood using nlmixr2 Thursday 15:00-16:30 |
| IV-044 Van Thuy Truong Stochastic pharmacodynamics: Drug effects on the time to extinction of a heterogeneous tumour cell population Thursday 15:00-16:30 |
| IV-058 Martijn van Noort User-friendly parameter identifiability methods with a workflow to guide model development, using categorical and continuous scales Thursday 15:00-16:30 |
| IV-067 Esmée Vendel Belimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis Thursday 15:00-16:30 |
| IV-071 Roberto Visintainer stormTB: SimulaTOR of a murine Minimal-pbpk model for anti-TB drugs Thursday 15:00-16:30 |
| IV-072 Alina Volkova Mathematical modeling of autoimmune diseases: a systematic review and analysis for advancing therapeutic development Thursday 15:00-16:30 |
| IV-074 Camille Vong Multi-Endpoint Item-Response Modelling for Integrating Several Endpoints in Alzheimer’s Disease Drug Trials Thursday 15:00-16:30 |
| IV-077 My Luong Vuong Multiple imputation to handle missing covariate data in pharmacometrics modelling Thursday 15:00-16:30 |
| IV-081 Sebastian Weber Novel integrated population PD modeling framework to inform decision making during Oncology phase I dose-escalation Thursday 15:00-16:30 |
| IV-086 Marie Wijk A pragmatic approach to handling data below the lower limit of quantification in complex pharmacokinetic models Thursday 15:00-16:30 |
| IV-113 Manuela Zimmermann NLME modelling from a causal inference perspective when the dose-exposure-response relationship is confounded by the treatment regimen Thursday 15:00-16:30 |
| IV-116 Laura Zwep Statistical interaction modeling in non-linear mixed effect models: a case study in neonatal pharmacology Thursday 15:00-16:30 |
